Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Digital Money is Still Money

Electronic payment technology is becoming the de-facto option across numerous industries. On this episode of MarketScale’s Software and Technology podcast, Adi Ekshtain, Co-Founder of Amaryllis Payment Solutions, and Viko Bargig, Solutions Architect for Amaryllis, sat down with Sean Heath to discuss the challenges of developing the latest and greatest technologies. The world is moving…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Electronic payment technology is becoming the de-facto option across numerous industries. On this episode of MarketScale’s Software and Technology podcast, Adi Ekshtain, Co-Founder of Amaryllis Payment Solutions, and Viko Bargig, Solutions Architect for Amaryllis, sat down with Sean Heath to discuss the challenges of developing the latest and greatest technologies.

The world is moving toward the several digital transaction types more quickly each day, but the basic nature of the transaction remains quite simple, Ekshtain said. “There is a lot of commonality between different payment modalities and one of them is, of course, there is a payer and a payee.”

The perceived challenge in managing all of these different payment processes is actually less difficult than one would expect, explained Bargig. “It’s not difficult. It’s more the responsibility aspect of the business. It’s to make sure that everything is always up and running and everything is always available and accessible, regardless of the action or transaction you are trying to process.”

Ekshtain also explained that all of the various currencies, both physical and digital, are easily added to the system Amaryllis has created.

“We can plug them into our platform. We can accept them and, where possible, we can even disburse funds using those currencies. So, for us, we don’t look at them as the competition. We look at them as part of our ecosystem.”

For the latest news, videos, and podcasts in the Software & Technology Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512